Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis
The objective of this ar ticle is to provide an overview of literature on pharmacological and non-pharmacological strategies employed in the management of neuropathic pain in multiple sclerosis. Pharmacological options include cannabinoids, muscle relaxants (tizanidine, baclofen, dantrolene), anticonvulsants (benzodiazepine s, gabapentin, phenytoin, carbamazepine, lamotrigine), antidepressants (duloxetine, venlafaxine, tricyclic antidepressants), opioids (naltrexone), and botulinum toxin variants, which have evidence from various clinical trials. Non-pharmacological approaches for trigeminal neuralgia may include neuro sur...
Source: CNS Drugs - February 29, 2024 Category: Neurology Source Type: research
Dose-dependent effect of lamotrigine on quetiapine serum concentration in patients using instant release tablets
ConclusionThe effect of lamotrigine in reducing quetiapine concentration is only significant for patients using quetiapine IR tablets who are treated with lamotrigine doses > 200 mg/day. Because of high variability in the interaction effect, TDM of quetiapine should be recommended during co-prescription of high-dose lamotrigine. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - February 23, 2024 Category: Drugs & Pharmacology Source Type: research
Care of pharmaco-resistant absence seizures in childhood
Rev Neurol (Paris). 2024 Feb 21:S0035-3787(24)00026-2. doi: 10.1016/j.neurol.2024.01.002. Online ahead of print.ABSTRACTIn childhood absence epilepsy, pharmaco-resistance occurs in 20-30% of patients. In that situation, glucose transporter type 1 deficiency has to be ruled out, especially if absences started before the age of four years and if neurological signs are present. If ethosuximide, valproate and lamotrigine have failed in monotherapy or in association, there are currently no valuable therapeutic options. The same rules apply for epilepsy with myoclonic absences. Importantly, arguments supporting that making the p...
Source: Revue Neurologique - February 22, 2024 Category: Neurology Authors: M Le Roux N Benallegue S Gueden M Rupin-Mas P Van Bogaert Source Type: research
Efficacy and Tolerability of Adjunctive Brivaracetam in Patients with Focal-Onset Seizures on Specific Concomitant Antiseizure Medications: Pooled Analysis of Double-Blind, Placebo-Controlled Trials
CONCLUSION: BRV was efficacious and well tolerated regardless of the specific concomitant ASMs used as part of their treatment regimen. These data show that in patients with focal-onset seizures, BRV provides additional efficacy to a broad range of ASMs.PMID:38356105 | DOI:10.1007/s12325-024-02795-z (Source: Adv Data)
Source: Adv Data - February 15, 2024 Category: Epidemiology Authors: Brian Moseley Dimitrios Bourikas Svetlana Dimova Sami Elmoufti Simon Borghs Source Type: research
Efficacy and Tolerability of Adjunctive Brivaracetam in Patients with Focal-Onset Seizures on Specific Concomitant Antiseizure Medications: Pooled Analysis of Double-Blind, Placebo-Controlled Trials
CONCLUSION: BRV was efficacious and well tolerated regardless of the specific concomitant ASMs used as part of their treatment regimen. These data show that in patients with focal-onset seizures, BRV provides additional efficacy to a broad range of ASMs.PMID:38356105 | DOI:10.1007/s12325-024-02795-z (Source: Adv Data)
Source: Adv Data - February 15, 2024 Category: Epidemiology Authors: Brian Moseley Dimitrios Bourikas Svetlana Dimova Sami Elmoufti Simon Borghs Source Type: research
Efficacy and Tolerability of Adjunctive Brivaracetam in Patients with Focal-Onset Seizures on Specific Concomitant Antiseizure Medications: Pooled Analysis of Double-Blind, Placebo-Controlled Trials
ConclusionBRV was efficacious and well tolerated regardless of the specific concomitant ASMs used as part of their treatment regimen. These data show that in patients with focal-onset seizures, BRV provides additional efficacy to a broad range of ASMs. (Source: Advances in Therapy)
Source: Advances in Therapy - February 15, 2024 Category: Drugs & Pharmacology Source Type: research
Antiepileptic Strategies for Patients with Primary and Metastatic Brain Tumors
Curr Treat Options Oncol. 2024 Feb 14. doi: 10.1007/s11864-024-01182-8. Online ahead of print.ABSTRACTSeizure activity is common in patients with primary and metastatic brain tumors, affecting more than 50% of cases over the course of their disease. Several mechanisms contribute to brain tumor-related epilepsy (BTRE), including a pro-inflammatory environment, excessive secretion of glutamate and an increase in neuronal excitatory tone, reduction of GABAergic inhibitory activity, and an increase in 2-hydroxygluturate production in isocitrate dehydrogenase mutant tumors. After a verified seizure in a brain tumor patient, the...
Source: Epilepsy Curr - February 14, 2024 Category: Neurology Authors: Herbert B Newton Jenna Wojkowski Source Type: research
Antiepileptic Strategies for Patients with Primary and Metastatic Brain Tumors
Curr Treat Options Oncol. 2024 Feb 14. doi: 10.1007/s11864-024-01182-8. Online ahead of print.ABSTRACTSeizure activity is common in patients with primary and metastatic brain tumors, affecting more than 50% of cases over the course of their disease. Several mechanisms contribute to brain tumor-related epilepsy (BTRE), including a pro-inflammatory environment, excessive secretion of glutamate and an increase in neuronal excitatory tone, reduction of GABAergic inhibitory activity, and an increase in 2-hydroxygluturate production in isocitrate dehydrogenase mutant tumors. After a verified seizure in a brain tumor patient, the...
Source: Epilepsy Curr - February 14, 2024 Category: Neurology Authors: Herbert B Newton Jenna Wojkowski Source Type: research
Antiepileptic Strategies for Patients with Primary and Metastatic Brain Tumors
Curr Treat Options Oncol. 2024 Feb 14. doi: 10.1007/s11864-024-01182-8. Online ahead of print.ABSTRACTSeizure activity is common in patients with primary and metastatic brain tumors, affecting more than 50% of cases over the course of their disease. Several mechanisms contribute to brain tumor-related epilepsy (BTRE), including a pro-inflammatory environment, excessive secretion of glutamate and an increase in neuronal excitatory tone, reduction of GABAergic inhibitory activity, and an increase in 2-hydroxygluturate production in isocitrate dehydrogenase mutant tumors. After a verified seizure in a brain tumor patient, the...
Source: Epilepsy Curr - February 14, 2024 Category: Neurology Authors: Herbert B Newton Jenna Wojkowski Source Type: research
Antiepileptic Strategies for Patients with Primary and Metastatic Brain Tumors
Curr Treat Options Oncol. 2024 Feb 14. doi: 10.1007/s11864-024-01182-8. Online ahead of print.ABSTRACTSeizure activity is common in patients with primary and metastatic brain tumors, affecting more than 50% of cases over the course of their disease. Several mechanisms contribute to brain tumor-related epilepsy (BTRE), including a pro-inflammatory environment, excessive secretion of glutamate and an increase in neuronal excitatory tone, reduction of GABAergic inhibitory activity, and an increase in 2-hydroxygluturate production in isocitrate dehydrogenase mutant tumors. After a verified seizure in a brain tumor patient, the...
Source: Epilepsy Curr - February 14, 2024 Category: Neurology Authors: Herbert B Newton Jenna Wojkowski Source Type: research
Antiepileptic Strategies for Patients with Primary and Metastatic Brain Tumors
Curr Treat Options Oncol. 2024 Feb 14. doi: 10.1007/s11864-024-01182-8. Online ahead of print.ABSTRACTSeizure activity is common in patients with primary and metastatic brain tumors, affecting more than 50% of cases over the course of their disease. Several mechanisms contribute to brain tumor-related epilepsy (BTRE), including a pro-inflammatory environment, excessive secretion of glutamate and an increase in neuronal excitatory tone, reduction of GABAergic inhibitory activity, and an increase in 2-hydroxygluturate production in isocitrate dehydrogenase mutant tumors. After a verified seizure in a brain tumor patient, the...
Source: Epilepsy Curr - February 14, 2024 Category: Neurology Authors: Herbert B Newton Jenna Wojkowski Source Type: research
